Skip to main content
MED $11.44 -0.35%
MED logo

MED · Medifast Inc

Track MED — free
$11.44 -0.04 (-0.35%) At close · Aug 14
Market Cap
$127.91M
Shares
11.18M
All earnings calls

Earnings call · FY2026 Q1

Medifast Inc Q1 FY2026 Earnings Call

Medifast Inc Q1 FY2026 Earnings Call

Concluded May 4, 2026 Audio replay
May 4, 2026 38:15 28 turns
Period
FY2026 Q1
Runtime
38:15
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

Medifast reported Q1 2026 revenue of $76.0 million, down 34.3% year-over-year, posting a net loss of $2.1 million ($0.19 per diluted share) amid a continued decline in active earning coaches to 14,000, though the company highlighted its first sequential quarterly revenue growth in three years and a 19.2% increase in revenue per active earning coach as signs of stabilization under its metabolic health strategy.

Metabolic health repositioning 31 Coach productivity and field execution 28 Body composition and clinical outcomes 15 CEO transition 14 GLP-1 disruption and competitive positioning 8 New product launch and convention 8

Management tone

Positive

Net tone +25 · moderate hedging

Grounding quotes
  • “We are seeing further evidence that our business is at the beginning of a period of stabilization and that we are making meaningful progress in delivering tangible traction in the market.”
  • “the number of active earning coaches continues to decline, the first quarter saw our first sequential quarterly revenue growth in three years”
  • “We are not going to predict exactly which quarter, but based on history, we believe that is going to happen in a short period of time.”

Forward guidance

4 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue $76.04M -34.3% YoY
Diluted EPS -$0.19
Gross margin 68.1% -4.7 pp YoY
Net income -$2.12M

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • First sequential quarterly revenue growth in three years
  • Revenue per active earning coach rose 19.2% year-over-year to $5,432 from $4,556, driven by an increasing number of clients per coach
  • Cost realignment expected to generate more than $30 million in future savings
  • SG&A as a percentage of revenue decreased 150 basis points year-over-year to 72.4%
  • Second consecutive quarter of year-over-year coach productivity gains, with strong coach leadership advancement and improved client acquisition percentages
  • New comprehensive metabolic system launching later this year, with pilot feedback described as highly encouraging

Risks & pressure points

  • Revenue declined 34.3% year-over-year to $76.0 million from $115.7 million
  • Active earning coaches fell 44.9% to 14,000 from 25,400, and the company expects the number of active earning coaches to continue to decline in 2026
  • Net loss of $2.1 million, or $0.19 per diluted share, compared to prior-year profit metrics
  • Loss from operations widened to $3.3 million (4.3% of revenue) from $1.3 million (1.1% of revenue)
  • Gross profit margin contracted to 68.1% from 72.8% due to loss of leverage on fixed costs
  • Gross profit decreased 38.6% to $51.8 million from $84.2 million on lower sales volumes

Key moments

Jump directly to management's words in the synchronized transcript.

“As we speak today, I am pleased to report that those early indicators have continued to strengthen. We are seeing further evidence that our business is at the beginning of a period of stabilization and that we are making meaningful progress in delivering tangible traction in the market.” Daniel R. Chard, CEO
“Our balance sheet remains strong, with substantial cash and investments of approximately $169 million, marginally higher than in Q4, and no debt. This positions us well as the business stabilizes and we reestablish revenue growth.” Daniel R. Chard, CEO

Forward guidance

From the 8-K filed May 4, 2026.

Metric Guided
Revenue
second quarter 2026
$60M – $80M
Loss per share
second quarter 2026
$-1.00 – $-0.50
Revenue
full year 2026
$270M – $300M
Loss per share
full year 2026
$-2.75 – $-1.55
Full-screen source Call document